COMPANY PROFILE

 Incorporated on 16th June, 1961 at Delhi.

 Manufacture drugs, medicines, cosmetics and chemical products.
 Research based, export oriented, and innovative international Pharma
Company.
 In 2008 acquired by Daiichi Sankyo japanese co.
 Global company, present in 40 countries and manufacturing facilities in
6 countries- USA, Ireland, Nigeria, China, Malaysia and India.
 First Indian pharma company having global ambitions to go into full-
fledged marketing across the world - 50% of the company’s sales come
from exports.
 Presence in niche therapeutic segments & is the unbeatable leader in
the antibiotics segment.
 Subsidiaries :-

1.Domestic :- Solus Pharma (Marketing of Bulk Drugs &

Pharmaceutical formulations)
Rexcel Pharma (Marketing of Pharmaceutical formulations)
Ranbaxy Fine Chemicals(Reagents & specialty chemicals)  
Vorin Labs(Manufacture and marketing of bulk drugs)
Vidyut Investments (Investments, Trade finance)
Vidyut Travel Services(Leasing of Aircraft)
Ranbaxy Drugs & Chemicals.
2.OVERSEAS:-
 Ranbaxy Guangzhou, China(Marketing of pharmaceutical
formulations)
Ranbaxy Netherlands B.V.
Ranbaxy Nigeria
Ranbaxy Hong Kong (Manufacture and trading of pharmaceuticals)
 SWOT ANALYSIS
STRENGTH
 Low cost of production
 Efficient technologies for Large no. of generics.
 Large pool of skilled technical manpower.
 Increasing libaralisation of govt. policies.

WEAKNESS
 Fragmentation of installed policies.
 Lows technology level of capital goods.
 Non availability of major intermediaries for bulk drugs.
 Lack of experience to exploit effeciently the new patent resume.
 Very low key R & D.
Low share of India world pharmaceutical product.
 Lack of experience in international trade.
OPPORTUNITY
 Aging of the world population
 New diagnoses & social diseases.
 Saturation Point of market is faraway.
 New market places are still not explored.
 New therapy approaches.

THREAT
 Rising healthcare cost.
 High cost in R & D.
 High entry cost in new market.
 Competition from other generic products.
 Products of RLL

PRODUCTS THERAPEUTIC CATEGORY

 Antibiotic Loxof, Cefrain, Roscillin, Keflor, Cefran CT
Sporidex, Mox, Zanocin
 Cholestrol Reducer Pravator, Simvotin,Storvas
 Anti AIDS Colcibra, Rofibax
 Gastrointestinal Romesec
 Antiulcer Omezec, Histac
 ErectileDysfunctiona(male) Caverta, forzest
 Anti depressant Venla
 Antihypertensive Quinapril,Corpil,Candesar
 Antidiahorreal Cutizone
 Anti Diabetic Pioglar, Regan,Vogseal
 Burns Silverex
 Cough Syrup Chericof
 Sedative Calmpose
 AntiCancer Metformin
 Oral Solution Loratadine Syrup
 Asthma Clafrinast
 Vitamins & minerals Revital, Reconia
 NSAIDS Volini
 Analgesic Fortwin
 Herbal products Olesan Oil (Cold)
Olesan(cough syrup) Eat
Ease(Apetite Enhancer)
 Dairy Cattle Yeasacc
 COMMUNICATION MIX

 Rextar :- Recruited 225 additional field staff.

 Cifran task force:- Inducted 50 representatives.
 HDL (hypertension, diabetes and lipid lowering) taskforce:- 24 representatives.
 Website for the doctors for the products promotion & web based
supplier collaboration.
 Consumer Contact Programs at different places.
 Television Advertisement.
 INTERESTING FACTS
 First Indian Co. to explore foreign market.
 11th largest co. in international generic market.
 Ranked among top ten generic co.s in US.
 Ranked 3rd generic co. in Brazil.
 First co. to file an investigational new drug application for its new asthma
molecule Rbx-4638 with the DCGI.
 Brought new mechanism for treating asthma (CLAFRINAST).
 First to launch high end anti infective injectible.
 Highest Indian pharmaceutical co. in US with more than 40 approved
products.
 First to launch Roliflo OD (NDDS product).
THANK YOU
BY:- SHROMA